Annals of Oncology
Author:
Keywords:
Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Carcinoma, Squamous Cell, Cetuximab, Female, Head and Neck Neoplasms, Humans, Male, Middle Aged, Quinazolines, Receptor, Epidermal Growth Factor, Receptor, ErbB-2, Treatment Outcome, Young Adult, Science & Technology, Life Sciences & Biomedicine, Oncology, afatinib, cetuximab, recurrent HNSCC, metastatic HNSCC, EGFR inhibitor therapy, QUALITY-OF-LIFE, EUROPEAN-ORGANIZATION, LUNG ADENOCARCINOMA, PLUS CETUXIMAB, CANCER, INHIBITOR, ERLOTINIB, TOXICITY, TRIALS, GROWTH, Afatinib, ErbB Receptors, Squamous Cell Carcinoma of Head and Neck, Receptor, erbB-2, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, 3202 Clinical sciences, 3211 Oncology and carcinogenesis
Abstract:
Afatinib is an oral, irreversible ErbB family blocker that has shown activity in epidermal growth factor receptor (EGFR)-mutated lung cancer. We hypothesized that the agent would have greater antitumor activity compared with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients, whose disease has progressed after platinum-containing therapy.